Once-daily liraglutide versus lixisenatide as Add-on to Metformin in type 2 diabetes: A 26-week randomized controlled clinical trial

Diabetes Care

Volumn 39, Issue 9, 2016, Pages 1501-1509

  Nauck, Michael ^a   Rizzo, Manfredi ^b   Johnson, Andrew ^c   Bosch Traberg, Heidrun ^d   Madsen, Jesper ^d   Cariou, Bertrand ^e  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY OF PALERMO   (Italy)

^c SOUTHMEAD HOSPITAL   (United Kingdom)

^d NOVO NORDISK A S   (Denmark)

^e NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PEPTIDE;

ABDOMINAL DISTENSION; ACUTE MYELOBLASTIC LEUKEMIA; ADD ON THERAPY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERAMYLASEMIA; HYPOGLYCEMIA; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; VOMITING; WEIGHT REDUCTION; BLOOD; BODY WEIGHT; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; MIDDLE AGED; POSTPRANDIAL STATE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; POSTPRANDIAL PERIOD; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84986229303     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-2479     Document Type: Article

References (40)

1. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38:140-149
3. Jespersen MJ, Knop FK, ChristensenM. GLP-1 agonists for type 2 diabetes: Pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol 2013;9:17-29
4. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: Properties, functions, and clinical implications. Am J Med 2011;124 (Suppl.):S3-S18
5. Ryan D, Acosta A. GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. Obesity (Silver Spring) 2015;23:1119-1129
6. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:728-742
7. Annex I: Summary of product characteristics [Internet], 2014. Available from http://www .ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002445/ WC500140401.pdf. Accessed 5 November 2015
8. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43:1664-1669
9. Liraglutide (NN2211). Abbreviated Investigator's Brochure. Edition 16. Bagsværd, Denmark, Novo Nordisk A/S, 2014
10. Buse JB, Rosenstock J, Sesti G, et al.; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, openlabel trial (LEAD-6). Lancet 2009;374:39-47
11. Pratley RE, NauckMA, Bailey T, et al.; 1860- LIRA-DPP-4 Study Group. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: A randomized, open-label trial. Diabetes Care 2012;35:1986-1993
12. Garber A, Henry R, Ratner R, et al.; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double- blind, parallel-treatment trial. Lancet 2009; 373:473-481
13. Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B; LEAD-3 (Mono) Study Group. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 2011;13:348-356
14. Marre M, Shaw J, Brändle M, et al.; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-278
15. NauckM, Frid A, Hermansen K, et al.; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009;32:84-90
16. Nauck M, Frid A, Hermansen K, et al. Longterm efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab 2013;15:204-212
17. Pratley RE, Nauck M, Bailey T, et al.; 1860- LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-1456
18. Pratley R, Nauck M, Bailey T, et al.; 1860- LIRA-DPP-4 Study Group. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: A randomised, parallel-group, openlabel trial. Int J Clin Pract 2011;65:397-407
19. Russell-Jones D, Vaag A, Schmitz O, et al.; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Diabetologia 2009;52:2046-2055
20. Zinman B, Gerich J, Buse JB, et al.; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32: 1224-1230
21. Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept 2010;164:58-64
22. Charbonnel B, Bertolini M, Tinahones FJ, Domingo MP, Davies M. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: A meta-analysis. J Diabetes Complications 2014; 28:880-886
23. Raccah D, Gourdy P, Sagnard L, Ceriello A. Lixisenatide as add-on to oral anti-diabetic therapy: An effective treatment for glycaemic control with body weight benefits in type 2 diabetes. Diabetes Metab Res Rev 2014;30: 742-748
24. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline. Guideline for good clinical practice E6(R1) [Internet], 1996. Available from http://www.ich.org/ fileadmin/Public-Web-Site/ICH-Products/ Guidelines/Efficacy/E6/E6-R1-Guideline.pdf. Accessed 5 November 2015
25. World Medical Association. WMA Declaration of Helsinki. Ethical principles for medical research involving human subjects [Internet], 2008. Available from http://www.wma.net/ en/30publications/10policies/b3/. Accessed 5 November 2015
26. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: A report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28:1245-1249
27. Buse JB, Garber A, Rosenstock J, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab 2011;96:1695-1702
28. Kapitza C, Forst T, Coester HV, Poitiers F, Ruus P, Hincelin-Méry A. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab 2013;15:642-649
29. Meier JJ, Rosenstock J, Hincelin-Méry A, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: A randomized, open-label trial. Diabetes Care 2015;38: 1263-1273
30. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study. Lancet 2013; 381:117-124
31. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): A randomised, open-label, phase 3, non-inferiority trial. Lancet 2014;384:1349-1357
32. Pratley RE, Nauck MA, Barnett AH, et al.; HARMONY 7 study group. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): A randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2014;2: 289-297
33. Fonseca VA, Devries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications 2014;28: 399-405
34. Bentley-Lewis R, Aguilar D, Riddle MC, et al.; ELIXA Investigators. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J 2015;169: 631-638.e7
35. Pfeffer MA, Claggett B, Diaz R, et al.; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-2257
36. Marso SP, Poulter NR, Nissen SE, et al. Design of the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial. Am Heart J 2013;166: 823-30.e5
37. Steinberg WM, Nauck MA, Zinman B, et al.; LEADER Trial investigators. LEADER 3-lipase and amylase activity in subjects with type 2 diabetes: Baseline data from over 9000 subjects in the LEADER Trial. Pancreas 2014;43: 1223-1231
38. Daniels GH, Hegedüs L, Marso SP, et al.; LEADER Trial Investigators. LEADER 2: Baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: Preliminary observations. Diabetes Obes Metab 2015;17: 477-486
39. Lando HM, Alattar M, Dua AP. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidylpeptidase- 4 inhibitors in the outpatient setting. Endocr Pract 2012;18:472-477
40. Tokuyama H, Kawamura H, Fujimoto M, et al. A low-grade increase of serum pancreatic exocrine enzyme levels by dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes. Diabetes Res Clin Pract 2013;100:e66-e69